Business
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation.
About this update from Ginkgo Bioworks Holdings, Inc.
[{"type":"text","content":"BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation.","length":529,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Ginkgo Bioworks)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Ginkgo Bioworks)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/fe3c2abd5acfb0739db965e53a5bec87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pD7D8Jpi1nYhM2EkNRaAzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fe3c2abd5acfb0739db965e53a5bec87","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1583909/Ginkgo_Logo_Lockup.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Mr. Coen joined the Company on May 1, 2023 with over 30 years of public accounting and corporate finance leadership experience. Prior to his role at Ginkgo, Mr. Coen was the Corporate Vice President and Corporate Controller for Charles River Laboratories, a publicly held global contract research organization for pharmaceutical and biotechnology companies, governmental agencies and leading academic institutions, with approximately 20,000 employees across 150 locations in over 20 countries and annual revenues of approximately $4.0 billion. Prior to that, Mr. Coen served in accounting and finance leadership roles in the technology and medical device industries after spending more than 17 years in the audit practice at Deloitte & Touche LLP.","length":751,"tagName":"p"},{"type":"text","content":""We thank Mark for his dedicated service to the Company and his leadership of the finance team through many transformational phases at Ginkgo and wish him well in his next opportunity," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "I'm excited to elevate Steve to his new role stewarding the finance and acc...